Recent progress in conventional and biologic therapy for systemic lupus erythematosus.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23253930.
- Also identified by DOI 10.1136/annrheumdis-2012-202204.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The recent approval of belimumab for the treatment of systemic lupus erythematosus (SLE) ended a decade in which there was mounting optimism about the prospect for developing biologically based therapies for SLE. During this same period, steady progress had been made in understanding and applying conventional therapies for SLE. These advances in the use of conventional therapies provide an important frame of reference for evaluating the novel biologic therapies that are expected to emerge in the near future.
Medical subject headings
- Antirheumatic Agents
- Biological Products
- Lupus Erythematosus, Systemic